REPL
Replimune Group, Inc.
NASDAQ · Healthcare · Biotechnology · US
$20.77
+0.56%Margins
Gross margin
—
EBITDA margin
—
EBIT margin
—
Net margin
—
FCF margin
—
-132.4%
Return on equity
-72.5%
Return on assets
-81.3%
Return on invested capital
0.00x
Asset turnover
-$245.5M
Cash from operations
$3.25
Cash per share
Margins, returns on capital and operating efficiency from the latest trailing period · Data as of Sep 1, 2026